Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS)

NCT03756974 is registered in ClinicalTrials.gov with Bionorica SE as lead sponsor.

NCT NCT03756974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03756974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS)
Lead sponsor
Bionorica SE
Phase
Phase 3
Overall status
Completed
Start date
February 18, 2019
Completion date
March 30, 2021
Enrollment
397 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity due to multiple sclerosis